In yet another demonstration of how far drug pricing concerns are invading the hitherto sacrosanct territory of drug development, a consortium of national advisory bodies on pricing have written to the chief official responsible for European Union drug research.
Dr. Anuj Gupta explains the potential implications of the GST- or the goods and services tax - on Indian pharma.
Pharmaceutical Executive
The EU’s proposed new study on off-label prescribing is just another way of kicking the subject into the long grass.
Pharmaceutical Executive
Energy reform may be stealing the headlines in Mexico, but a rising regulatory authority, the beginnings of healthcare reform, and cost-competitive manufacturing are fueling future growth in the country’s pharma industry-for domestic and global players alike.
The results of this year’s survey indicate that the media’s scrutiny of pharma increased in 2014,with drug safety again again sitting atop of the list of hot button issues.
The EU’s proposed new on off-label prescribing is just another way of kicking the issue into the long grass, writes Reflector.
March 11, 2015.
Just as the medicine adaptive pathways to patients (MAPPs) gains currency in the world of medicine, the EU has come up with STAMP, a new expert group intended to assist the process, but which might well suffocate it. Reflector reports.
President Obama's January announcement of an initiative in precision medicine has set Europe a-flutter over the term 'personalized medicine', writes Peter O'Donnell.
The debate around NICE's threshold for cost effectiveness has always been heated; recent theories add more fuel to the fire, writes Leela Barham.
Pharmaceutical Executive
New EU group could ultimately end up handcuffing much-needed efforts to modernize drug authorization.
South Africa may have the most developed market for biopharmaceuticals on the African continent, but there are a few critical shortcomings, writes William Looney.
February 17, 2015.
The European Commission’s (EC) decision to withdraw its investigation into the UK Government's Patent Box scheme is positive news for British innovators, writes Michael Jaeger.
Pharmaceutical Executive
A new analysis shows South Korea to be the most attractive early phase destination based on the availability of global and regional suppliers, patient pool and the current regulatory scenario of the country.
The French pharmaceutical market is forecast to grow at a "tepid" CAGR of 0.7% from $46.2 billion in 2014 to $48.2 billion by 2020, according to GlobalData.
Pharma and healthcare are among the many areas being viewed with increasing attention inside and outside Greece, following the victory in the country’s elections of the radical left-wing, anti-austerity Syriza party.
Pharmaceutical Executive
New competition commissioner steps into the unenviable role of trying to solve two particularly contentious pharma firestorms.
Pharmaceutical Executive
With a track record of surviving successive economic crises, the battle-tested Argentinian pharma industry has developed into a powerful leader in markets across the Latin America region.
Findings from the joint report on the occurrence of antimicrobial resistance in bacteria from humans and food-producing animals.
Franz Humer, former CEO and chairman of Roche, has joined BIAL, Portugal's largest pharma company, as a non-executive board member.
Several vaccine candidates are moving into larger clinical trials, supported by government and industry efforts to address manufacturing and research challenges. Jill Wechsler reports.
2014 was a banner year for investment in biotech, and there is little sign of decline. With an unprecedented $100m Series C round of financing, Innovent has demonstrated this optimism extends as far as China.
Brussels correspondent Reflector asks, what attitude will the new EC for competition, Margrethe Vestager, adopt to the pharmaceutical industry?
